Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials

IMPORTANCE: Demonstrating the value of therapies from a patient’s perspective is increasingly important for patient-centered care. OBJECTIVE: To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and men...

Descripción completa

Detalles Bibliográficos
Autores principales: Augustin, Matthias, Lambert, Jo, Zema, Carla, Thompson, Elizabeth H. Z., Yang, Min, Wu, Eric Q., Garcia-Horton, Viviana, Geng, Ziqian, Valdes, Joaquin M., Joshi, Avani, Gordon, Kenneth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557488/
https://www.ncbi.nlm.nih.gov/pubmed/33052382
http://dx.doi.org/10.1001/jamadermatol.2020.3617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557488/
https://www.ncbi.nlm.nih.gov/pubmed/33052382
http://dx.doi.org/10.1001/jamadermatol.2020.3617

Ejemplares similares